Prothena Corporation plc (PRTA) Earnings
Prothena Corporation plc is expected to report next earnings on August 3, 2026 (in NaN days), with a consensus EPS estimate of $-0.39. PRTA has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise +59.1% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.31 | $0.52 | +267.7% | $51M | +6215.2% |
| Feb 19, 2026 | $-0.45 | $-0.44 | +2.2% | $21000 | -98.4% |
| Nov 6, 2025 | $-0.60 | $-0.67 | -11.7% | $2M | +262.2% |
| May 8, 2025 | $-0.92 | $-1.12 | -21.7% | $3M | -81.6% |
| Feb 20, 2025 | $-1.02 | $-1.08 | -5.9% | $2M | -71.8% |
| Aug 8, 2024 | $-1.05 | $1.22 | +216.2% | $132M | +1130.3% |
| Feb 15, 2024 | $-1.23 | $-1.26 | -2.4% | $316000 | -85.3% |
| Nov 2, 2023 | $-0.32 | $0.38 | +218.8% | $85M | +103.6% |
| Aug 3, 2023 | $-0.92 | $-1.03 | -12.0% | $4M | -11.1% |
| May 4, 2023 | $-0.83 | $-0.89 | -7.2% | $2M | -52.0% |
| Feb 23, 2023 | $-0.47 | $0.12 | +125.5% | $50M | +577.4% |
| Nov 3, 2022 | $-0.31 | $-0.97 | -212.9% | $2M | -94.0% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2025 · February 19, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Prothena saw significant progress in 2025 clinical pipeline with 2 partner programs advancing to Phase III. Roche advanced prasinezumab to Phase III PARAISO trial for Parkinson's disease. Novo Nordisk advanced coramitug to Phase III CLEOPATTRA trial for ATTR-CM. Collaborations with BMS progressed with Phase II TargetTau-1 trial and Fast Track designation. Introduced CYTOPE technology for intracellular targeting. 2026 priorities include capturing value from partnerships, share redemption program, and advancing preclinical portfolio.
Guidance
2026 net cash used in operating and investing activities expected to be between $50M - $55M. Potential aggregate clinical milestone payments up to $105M in 2026 from coramitug and PRX019.
Segment performance
Not applicable as focus is on R&D and partnerships rather than traditional product segment financials
Risks & headwinds
Risks associated with forward-looking statements including actual results differing from expectations, as per press release and SEC filings.
Analyst Q&A
Q: With primary completion dates for partnered program trials not until 2029, walk through key milestones in 2026-2027.
A: Expect to share CYTOPE activities, data from BMS tau program in H1 2027, and 2 Phase III readouts in 2029.
Q: Elaborate on PRX012 transferrin receptor tech.
A: Transferrin-based approach offers potential improvement in amyloid removal and ARIA-E profile.
Q: Plans for PRX019 Phase I study.
A: Phase I to complete in 2026, data to be shared with BMS.
Q: Data needed for CYTOPE platform partnership.
A: Exciting in vivo data from TDP-43 CYTOPE program, broad therapeutic area applications.